Clinical Trial Update: Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing long-term safety and tolerability of HSK39297 in patients with paroxysmal nocturnal hemoglobinuria is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• HSK39297

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: RECRUITING